However, combination of histone deacetylase (HDAC) inhibitors OKI-179 and nivolumab further inhibited cancer cell growth, therefore indicating that HDAC inhibitors could improve anti-tumor immune responses in cancers (124). The gene discussed is HDAC9; the disease is cancer.